tldrdailynews.com logo
Tag

Health And Biotech

All articles tagged with #health and biotech

NIH Launches Public-Private Cancer Vaccine Initiative to Accelerate Personalized Treatments
health-and-biotech3 days ago

NIH Launches Public-Private Cancer Vaccine Initiative to Accelerate Personalized Treatments

The National Institutes of Health (NIH) is launching a public-private partnership in December to accelerate the development of personalized cancer vaccines. This initiative, modeled after the rapid success of COVID-19 vaccines, aims to reduce the timeline for bringing new treatments to market from 8-15 years to 7-10 years. The program will initially focus on pancreatic, liver, and colorectal cancers, as well as pediatric tumors. The announcement triggered a significant rally in vaccine-related stocks, with Novavax and Moderna leading gains, driven by the promise of faster clinical trials and reduced R&D costs for participating companies.

via Yahoo Finance|
#biotech-stocks#cancer-vaccines#clinical-trials
Merck’s $3B Eye Drug Hits Primary Goal but Raises Safety Concerns
health-and-biotech18 days ago

Merck’s $3B Eye Drug Hits Primary Goal but Raises Safety Concerns

Merck & Co. reported that its trispecific drug remigromig met its primary endpoint in the Brunello phase 2b/3 trial for diabetic macular edema (DME). The drug, acquired from EyeBio in a deal valued at up to $3 billion, demonstrated non-inferiority to the standard VEGF inhibitor ranibizumab at Week 52. While the results support the hypothesis that targeting the Wnt signaling pathway can improve visual outcomes, the trial revealed higher rates of adverse events, including proliferative diabetic retinopathy and vitreous hemorrhage, compared to the control. Merck plans to present these data at the American Academy of Ophthalmology Annual Meeting next month and is conducting further analyses to characterize the safety findings. A second trial for DME is ongoing and scheduled for primary completion in March 2027. The company is positioning remigromig as a complementary therapy for patients who do not respond to existing VEGF inhibitors, aiming to diversify its pipeline beyond Keytruda.

via Fierce Biotech|
#clinical-trials#diabetic-macular-edema#eyebio
Cancer Vaccine Market Set to Hit 36% CAGR as mRNA Breakthroughs Expand Beyond Melanoma
health-and-biotech21 days ago

Cancer Vaccine Market Set to Hit 36% CAGR as mRNA Breakthroughs Expand Beyond Melanoma

The global cancer vaccine market, valued at $335 million in 2025, is projected to grow at a 36% compound annual rate through 2036. This expansion is driven by the recent Phase 3 success of Moderna and Merck’s personalized mRNA vaccine for melanoma, alongside a broadening pipeline targeting lung, prostate, and pancreatic cancers. While the US dominates current sales, analysts note a persistent gap between early immune responses and late-stage clinical efficacy.

via PR Newswire|
#cancer-vaccines#health-and-biotech#immunotherapy
"Evaxion's Breakthrough: AI-Driven Cancer Vaccine Boosts Stock by 30%"
health-and-biotech2 years ago

"Evaxion's Breakthrough: AI-Driven Cancer Vaccine Boosts Stock by 30%"

Evaxion Biotech is leveraging AI-Immunology™ to develop tailored cancer vaccines targeting Endogenous Retroviruses (ERVs), an untapped source of tumor antigens, with the goal of providing treatment solutions to cancer patients unresponsive to conventional immunotherapy. The company aims to generate Proof-of-Concept data by the second half of 2024 and has presented recent insights at the American Society of Hematology Annual Meeting. ERVs, remnants of ancient viruses overexpressed in cancer, are promising targets for cancer vaccines, and AI-Immunology™ plays a crucial role in identifying therapeutically relevant ERV tumor antigens from genomic patient tumor data. Evaxion's AI-Immunology™ platform offers a scalable and adaptable approach to vaccine discovery for infectious diseases and cancers, revolutionizing the landscape of immunotherapy with personalized medicine.

via Yahoo Finance|
#ai-immunology#cancer-vaccines#ervs